Literature DB >> 25511190

Multiple myeloma and chronic leukaemias in 2014: improved understanding of disease biology and treatment.

Jesús F San-Miguel1, Hagop M Kantarjian2.   

Abstract

In 2014, strides were made in the care of haematological malignancies. In particular, the heterogeneity of multiple myeloma was unravelled, and new diagnostic criteria and frontline standards of care were proposed; new therapeutic approaches have been validated and approved in chronic lymphocytic leukaemia; and in chronic myeloid leukaemia, complete cytogenetic response was confirmed as the primary therapeutic end point.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25511190     DOI： 10.1038/nrclinonc.2014.216

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  9 in total

1.  Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

Authors:  Susan Branford; David T Yeung; Wendy T Parker; Nicola D Roberts; Leanne Purins; Jodi A Braley; Haley K Altamura; Alexandra L Yeoman; Jasmina Georgievski; Bronte A Jamison; Stuart Phillis; Zoe Donaldson; Mary Leong; Linda Fletcher; John F Seymour; Andrew P Grigg; David M Ross; Timothy P Hughes
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

2.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Authors:  Valentin Goede; Kirsten Fischer; Raymonde Busch; Anja Engelke; Barbara Eichhorst; Clemens M Wendtner; Tatiana Chagorova; Javier de la Serna; Marie-Sarah Dilhuydy; Thomas Illmer; Stephen Opat; Carolyn J Owen; Olga Samoylova; Karl-Anton Kreuzer; Stephan Stilgenbauer; Hartmut Döhner; Anton W Langerak; Matthias Ritgen; Michael Kneba; Elina Asikanius; Kathryn Humphrey; Michael Wenger; Michael Hallek
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

3.  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Authors:  Richard R Furman; Jeff P Sharman; Steven E Coutre; Bruce D Cheson; John M Pagel; Peter Hillmen; Jacqueline C Barrientos; Andrew D Zelenetz; Thomas J Kipps; Ian Flinn; Paolo Ghia; Herbert Eradat; Thomas Ervin; Nicole Lamanna; Bertrand Coiffier; Andrew R Pettitt; Shuo Ma; Stephan Stilgenbauer; Paula Cramer; Maria Aiello; Dave M Johnson; Langdon L Miller; Daniel Li; Thomas M Jahn; Roger D Dansey; Michael Hallek; Susan M O'Brien
Journal:  N Engl J Med       Date:  2014-01-22       Impact factor: 91.245

4.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Authors:  Lotfi Benboubker; Meletios A Dimopoulos; Angela Dispenzieri; John Catalano; Andrew R Belch; Michele Cavo; Antonello Pinto; Katja Weisel; Heinz Ludwig; Nizar Bahlis; Anne Banos; Mourad Tiab; Michel Delforge; Jamie Cavenagh; Catarina Geraldes; Je-Jung Lee; Christine Chen; Albert Oriol; Javier de la Rubia; Lugui Qiu; Darrell J White; Daniel Binder; Kenneth Anderson; Jean-Paul Fermand; Philippe Moreau; Michel Attal; Robert Knight; Guang Chen; Jason Van Oostendorp; Christian Jacques; Annette Ervin-Haynes; Hervé Avet-Loiseau; Cyrille Hulin; Thierry Facon
Journal:  N Engl J Med       Date:  2014-09-04       Impact factor: 91.245

Review 5.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Authors:  S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

6.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Authors:  María-Victoria Mateos; Miguel-Teodoro Hernández; Pilar Giraldo; Javier de la Rubia; Felipe de Arriba; Lucía López Corral; Laura Rosiñol; Bruno Paiva; Luis Palomera; Joan Bargay; Albert Oriol; Felipe Prosper; Javier López; Eduardo Olavarría; Nuria Quintana; José-Luis García; Joan Bladé; Juan-José Lahuerta; Jesús-F San Miguel
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

7.  Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

Authors:  Rüdiger Hehlmann; Martin C Müller; Michael Lauseker; Benjamin Hanfstein; Alice Fabarius; Annette Schreiber; Ulrike Proetel; Nadine Pletsch; Markus Pfirrmann; Claudia Haferlach; Susanne Schnittger; Hermann Einsele; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Gerhard Ehninger; Dominik Heim; Hermann Heimpel; Christoph Nerl; Stefan W Krause; Dieter K Hossfeld; Hans-Jochem Kolb; Joerg Hasford; Susanne Saußele; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

8.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

9.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Authors:  Jens G Lohr; Petar Stojanov; Scott L Carter; Peter Cruz-Gordillo; Michael S Lawrence; Daniel Auclair; Carrie Sougnez; Birgit Knoechel; Joshua Gould; Gordon Saksena; Kristian Cibulskis; Aaron McKenna; Michael A Chapman; Ravid Straussman; Joan Levy; Louise M Perkins; Jonathan J Keats; Steven E Schumacher; Mara Rosenberg; Gad Getz; Todd R Golub
Journal:  Cancer Cell       Date:  2014-01-13       Impact factor: 31.743
  9 in total
  4 in total

Review 1.  Chronic myeloid leukemia: reminiscences and dreams.

Authors:  Tariq I Mughal; Jerald P Radich; Michael W Deininger; Jane F Apperley; Timothy P Hughes; Christine J Harrison; Carlo Gambacorti-Passerini; Giuseppe Saglio; Jorge Cortes; George Q Daley
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

2.  Standardized assay for assessment of minimal residual disease in blood, bone marrow and apheresis from patients with plasma cell myeloma.

Authors:  Agnieszka Blum; Katy Haussmann; Mathias Streitz; Stephan Schlickeiser; Carola Tietze-Buerger; Igor Wolfgang Blau; Lutz Uharek
Journal:  Sci Rep       Date:  2019-02-27       Impact factor: 4.379

3.  Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease.

Authors:  Antonio Garcia-Gomez; Tianlu Li; Carlos de la Calle-Fabregat; Javier Rodríguez-Ubreva; Laura Ciudad; Francesc Català-Moll; Gerard Godoy-Tena; Montserrat Martín-Sánchez; Laura San-Segundo; Sandra Muntión; Xabier Morales; Carlos Ortiz-de-Solórzano; Julen Oyarzabal; Edurne San José-Enériz; Manel Esteller; Xabier Agirre; Felipe Prosper; Mercedes Garayoa; Esteban Ballestar
Journal:  Nat Commun       Date:  2021-01-18       Impact factor: 14.919

4.  Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma.

Authors:  Xinyi Chen; Jin Chen; Wenyan Zhang; Ruixue Sun; Ting Liu; Yuhuan Zheng; Yu Wu
Journal:  Oncotarget       Date:  2017-11-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.